Indication: For the treatment of disorders with symptoms of hallucinative hearing, seeing, and feeling; erroneous beliefs, unusual distrust, and sudden social isolation (also as maintenance therapy). Also indicated for the treatment of a hypereuphoric condition, feelings of having exceptional energy, needing less sleep than usual, very fast talking with fast-changing thoughts/ideas, and strong irritability (sometimes). Also indicated for the treatment of chronic aggressive behaviour and psychotic symptoms in dementia (only 1 mg doses).
Brand name: Bevilon (Organon GmbH), Risperidon (Janssen-Cilag GmbH).
Regulatory status: not available.
Launch date: 6 and 16 December 1993.